Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

INTRODUCTION: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after disease progression on atezolizumab-bevacizumab is unclear. METHODS: This multinational, multicenter, and retrospecti...

詳細記述

保存先:
書誌詳細
出版年:Liver Cancer
主要な著者: Yoo, Changhoon, Kim, Jwa Hoon, Ryu, Min-Hee, Park, Sook Ryun, Lee, Danbi, Kim, Kang Mo, Shim, Ju Hyun, Lim, Young-Suk, Lee, Han Chu, Lee, Joycelyn, Tai, David, Chan, Stephen Lam, Ryoo, Baek-Yeol
フォーマット: Artigo
言語:Inglês
出版事項: S. Karger AG 2021
主題:
Original Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077483/
https://ncbi.nlm.nih.gov/pubmed/33977087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000512781
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料